RayKnowChina Research Map
Shortlist0

Not yet recruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Zhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07770672, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed esophageal squamous cell carcinoma.

    Inclusion criterion 2

    Undergo both 18F-FDG and 68Ga-FAPI PET/CT imaging at baseline. For Stage 2, the participant's 18F-FDG and 68Ga-FAPI PET/CT parameters must meet the criteria of the prediction model for lack of pathologic complete response (non-pCR).

    Inclusion criterion 5

  3. A female participant of childbearing potential must have a negative serum pregnancy test within 72 hours before the first administration of study treatment, must not be breastfeeding, and must agree to use a highly effective method of contraception with an annual failure rate of less than 1%, such as an intrauterine device, oral contraceptive, or condom, throughout the study and until 2 months after the last dose of adebrelimab or 6 months after the last dose of chemotherapy, whichever is longer. A male participant with a female partner of childbearing potential must be surgically sterile or agree to use an effective method of contraception throughout the study and until 2 months after the last dose of adebrelimab or 3 months after the last dose of chemotherapy, whichever is longer. Sperm donation is not permitted during the study.

    Inclusion criterion 26

  4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.

    Inclusion criterion 7

  5. Hematologic function. No blood components, hematopoietic growth factors, leukocyte-elevating agents, platelet-elevating agents, or medications used to correct anemia are permitted within 14 days before the first administration of study treatment:

    Inclusion criterion 11

    Absolute neutrophil count ≥1.5 × 10\^9/L;

    Inclusion criterion 12

    Platelet count ≥100 × 10\^9/L;

    Inclusion criterion 13

    Hemoglobin ≥90 g/L.

    Inclusion criterion 14

    Total bilirubin ≤1.5 × the upper limit of normal (ULN);

    Inclusion criterion 16

    Alanine aminotransferase (ALT) ≤2.5 × ULN and aspartate aminotransferase (AST) ≤2.5 × ULN;

    Inclusion criterion 17

    Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min, calculated using the Cockcroft-Gault formula.

    Inclusion criterion 18

    International normalized ratio (INR) ≤1.5 × ULN;

    Inclusion criterion 20

    Activated partial thromboplastin time (aPTT) ≤1.5 × ULN.

    Inclusion criterion 21

  6. History of immunodeficiency, including a positive human immunodeficiency virus (HIV) test, another acquired or congenital immunodeficiency disorder, a history of organ transplantation, or a history of allogeneic bone marrow transplantation.

    Exclusion criterion 12

    Active hepatitis B, defined as hepatitis B virus DNA ≥2,000 IU/mL or ≥10\^4 copies/mL; or hepatitis C, defined as a positive hepatitis C virus antibody test together with hepatitis C virus RNA above the lower limit of detection of the assay.

    Exclusion criterion 20

  7. Pregnant or breastfeeding female participants.

    Exclusion criterion 21

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07770672, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Participants must meet all of the following criteria to be eligible for enrollment:

  • Voluntarily agree to participate in the study and provide written informed consent.
  • Histologically or cytologically confirmed esophageal squamous cell carcinoma.
  • Thoracic esophageal cancer assessed by computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT), or other appropriate imaging, with clinical stage II to IVA disease according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
  • Considered by a surgeon to be suitable for an R0 resection and planned to undergo surgery after completing neoadjuvant treatment.
  • Undergo both 18F-FDG and 68Ga-FAPI PET/CT imaging at baseline. For Stage 2, the participant's 18F-FDG and 68Ga-FAPI PET/CT parameters must meet the criteria of the prediction model for lack of pathologic complete response (non-pCR).
  • Aged 18 to 75 years, inclusive, with no restriction based on sex.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
  • No previous antitumor treatment for esophageal cancer, including radiotherapy, chemotherapy, surgery, or other antitumor treatment.
  • No contraindication to surgery.
  • Adequate major organ function, as defined by all of the following:
  • Hematologic function. No blood components, hematopoietic growth factors, leukocyte-elevating agents, platelet-elevating agents, or medications used to correct anemia are permitted within 14 days before the first administration of study treatment:
  • Absolute neutrophil count ≥1.5 × 10\^9/L;
  • Platelet count ≥100 × 10\^9/L;
  • Hemoglobin ≥90 g/L.
  • Biochemical function:
  • Total bilirubin ≤1.5 × the upper limit of normal (ULN);
  • Alanine aminotransferase (ALT) ≤2.5 × ULN and aspartate aminotransferase (AST) ≤2.5 × ULN;
  • Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min, calculated using the Cockcroft-Gault formula.
  • Coagulation function:
  • International normalized ratio (INR) ≤1.5 × ULN;
  • Activated partial thromboplastin time (aPTT) ≤1.5 × ULN.
  • Pulmonary function:
  • Forced expiratory volume in 1 second (FEV1) ≥1.2 L;
  • FEV1 percentage of predicted value (FEV1%) ≥50%;
  • Diffusing capacity of the lung for carbon monoxide (DLCO) ≥50%.
  • A female participant of childbearing potential must have a negative serum pregnancy test within 72 hours before the first administration of study treatment, must not be breastfeeding, and must agree to use a highly effective method of contraception with an annual failure rate of less than 1%, such as an intrauterine device, oral contraceptive, or condom, throughout the study and until 2 months after the last dose of adebrelimab or 6 months after the last dose of chemotherapy, whichever is longer. A male participant with a female partner of childbearing potential must be surgically sterile or agree to use an effective method of contraception throughout the study and until 2 months after the last dose of adebrelimab or 3 months after the last dose of chemotherapy, whichever is longer. Sperm donation is not permitted during the study.
  • Able and willing to comply with the study procedures and follow-up requirements.

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

  • Obvious invasion by the tumor or involved lymph nodes into organs adjacent to the esophageal lesion, including the pleura, pericardium, azygos vein, diaphragm, peritoneum, major arteries, vertebral body, or trachea.
  • Supraclavicular lymph node metastasis.
  • Diagnosis of another malignant tumor within 5 years before the first administration of study treatment, except for a malignancy with a low risk of metastasis or death and an expected 5-year survival rate greater than 90%. Participants with adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or a similar malignancy may be considered eligible.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  • Poor nutritional status, defined as a body mass index (BMI) of less than 18.5 kg/m2. A participant whose nutritional status is corrected through appropriate nutritional support before the initiation of treatment may still be considered eligible following assessment by the principal investigator.
  • History of an allergic reaction to a monoclonal antibody.
  • Receipt of any tumor-directed radiotherapy, chemotherapy, or other antitumor medication.
  • Use of immunosuppressive medication or systemic corticosteroid treatment for an immunosuppressive purpose within 2 weeks before the first administration of study treatment at a dose greater than 10 mg/day of prednisone or an equivalent dose. In the absence of an active autoimmune disease, inhaled or topical corticosteroids and adrenal corticosteroid replacement at a dose greater than 10 mg/day of prednisone or an equivalent dose are permitted.
  • Receipt of a live attenuated vaccine within 4 weeks before the first administration of study treatment.
  • Major surgery or severe trauma within 4 weeks before the first administration of study treatment.
  • Any active autoimmune disease or history of an autoimmune disease, including but not limited to interstitial pneumonitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism. Participants with hypothyroidism may be considered eligible after hormone replacement therapy. Participants with psoriasis or childhood asthma or allergy that has completely resolved and requires no intervention during adulthood may be considered eligible; however, participants requiring medical intervention with a bronchodilator are not eligible.
  • History of immunodeficiency, including a positive human immunodeficiency virus (HIV) test, another acquired or congenital immunodeficiency disorder, a history of organ transplantation, or a history of allogeneic bone marrow transplantation.
  • Poorly controlled cardiac symptoms or disease, including but not limited to:
  • New York Heart Association (NYHA) class II or higher heart failure;
  • Unstable angina;
  • Myocardial infarction within the previous year;
  • Clinically significant supraventricular or ventricular arrhythmia that has not received appropriate clinical intervention or remains poorly controlled after clinical intervention.
  • A serious infection of greater than Grade 2 according to the Common Terminology Criteria for Adverse Events (CTCAE) within 4 weeks before the first administration of study treatment, including severe pneumonia requiring hospitalization, bacteremia, or other serious infectious complications; evidence of active pulmonary inflammation on baseline chest imaging; signs or symptoms of infection within 14 days before the first administration of study treatment; or a requirement for oral or intravenous antibiotic treatment within that period. Prophylactic antibiotic use is permitted.
  • Active tuberculosis identified through medical history or CT examination; a history of active tuberculosis within 1 year before enrollment; or a history of active tuberculosis more than 1 year before enrollment without having received appropriate standard treatment.
  • Active hepatitis B, defined as hepatitis B virus DNA ≥2,000 IU/mL or ≥10\^4 copies/mL; or hepatitis C, defined as a positive hepatitis C virus antibody test together with hepatitis C virus RNA above the lower limit of detection of the assay.
  • Pregnant or breastfeeding female participants.
  • Any other factor that, in the investigator's judgment, may result in forced premature discontinuation from the study, including another serious illness requiring concomitant treatment, including a psychiatric disorder; alcohol abuse; drug abuse; or family or social circumstances that may affect the participant's safety or compliance.

Quoted from ClinicalTrials.gov, NCT07770672, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07770672, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07770672